-
Peaceful Repeat Vote in Douglas Ward 3 Amid Heightened Security
-
‘They want silence’: how the film NAZA is shaking Israel
-
Belgian Ambassador Marks King’s Day in Athens Amidst Strong Bilateral Trade Ties
-
Dún Laoghaire-Rathdown €335m Budget Faces Mixed Reaction Over Housing and Cost of Living
-
Rediff.com IPO Risks: Gmail Dominance and New Business Ventures
-
BING X: 22,624.66 SNC have disappeared at BingX – how safe are tokens on BingX? Will BingX’s MiCAR licence be suspended?
-
Dubai Police Expand Luxury Patrol Fleet with 525-hp Defender
-
Iran Strikes US Sites in Kuwait Following US Airstrikes on Qeshm Island
-
NuRAN Wireless Raises First Two Towers in Benin as 4G Rollout Beats Expectations in Cameroon and Ivory Coast
-
LHH ICEO Research Led by Harvard Business School Professor Maps Four Paths for Work Beyond the C-Suite
-
ESGold Expands Montauban Gold-Silver Property to Approximately 26,787 Hectares Through Strategic Claim Staking
-
Wedgewood Weddings Acquires Swan Lake Overlook, Where Alpacas, Deer, and Mountain Views Join the Guest List
-
DSS Announces Completion of Impact Biomedical Business Combination with Zoar Limited
-
Newsmax Expands Over-the-Air Reach with HC2 Broadcasting Distribution Agreement for Newsmax2
-
Impala and Philanthropy Southwest Launch Southwest Hub, Mapping Philanthropy Across Eight States
-
HTB Activ(TM) Trial Demonstrates Significant Improvement in Cognitive Abilities
-
Nixxy Announces 1-for-20 Reverse Stock Split
-
IGC Pharma Completes Dosing in Phase 2 CALMA Trial of IGC-AD1 for Agitation in Alzheimer's Dementia
-
The IRS Watchdog Just Published Its FY 2027 Challenges List - Clear Start Tax Explains Why Agency Strain Rarely Slows Down Collection Notices
-
Who Does the Best Deep Plane Facelift in Oklahoma?
-
Tocvan Defines Priority Gold Target Areas at Gran Pilar From Project-Wide Soil Sampling and Geologic Mapping; 225 Soils at or Above 100 ppb Gold
-
Rockhaven Announces Successful Completion of 2026 Klaza Bulk Sample Program
-
Silver Storm to Attend the 121 Mining Investment Conference in London, UK
-
American Resources Corporation Provides Strategic Business and Financial Reporting Update
-
Who Does the Best Deep Plane Facelift in Sarasota?
-
Jumia Reports Third Quarter 2026 Results
-
Ameriwest Advances Its Copper Focused Strategy Through Proposed Sale of Railroad Valley to Pure Energy Minerals
-
1933 Industries Completes LED Lighting Retrofit at Its 68,000 Sq. Ft. Cannabis Cultivation Facility in Las Vegas, Nevada - Ranks #3 in Cannabis Flower Sales
-
AbTherx Licenses Atlas(TM) Platform to Athenova Therapeutics for Next-Generation Targeted Alpha Radiopharmaceutical Discovery
-
DataMeds AI Subsidiary Helomics, Inc. Announces Cancer Target Discovery and Anticancer Peptides Drug Development Partnership With DiaGen AI, Inc.
-
What to Do When Two Households Become One
-
SmartBuyerAI Gives Car Buyers an Itemized Check of Dealer Offers as FTC Steps Up Price Transparency Enforcement
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 18
-
Fulcrum Metals PLC Announces Uranium Readings up to 0.42% U(3)O(8) at Charlot-Neely
-
Srixon Announces Buy 2, Get 1 Free Golf Ball Promotion
-
Ondas and Aston Martin Aramco Formula One Team Launch Multi-Year Partnership Built for "Speed to Decision"
-
Who Does the Best Testosterone Replacement Therapy in Las Vegas?
-
CMP 2026-2027 Nonprofit Leadership Pulse Check
-
Nexteer's HMDD Wins Innovation Awards from PACE Pilot, CES and AutoTech Breakthrough
-
Coa Wealth Launches AI-Powered Software That Functions as a Private Investment Office for Individual Investors and Families
-
More Than Keyboards: Epomaker Brings Its Gaming World to G-STAR 2026
-
Who Is the Best Spanish-Speaking Private Investigator in Sacramento?
-
Healixa Turns Patents Into Products: FrostPulse(TM) Delivered and Five Eternal Spring(TM) Units Enter Production
-
Leggett Dynamics Wins 2026 Automotive News PACE Pilot Award For Smart Brushless Motor
-
Cosmos Health Reports Record Nine-Month Revenue of $53.6 Million, Up 18%; Q3 Gross Margin Up 465 Basis Points Sequentially; Total Debt Down 34% and Stockholders' Equity Up 21% Since Year-End
-
Nearly Half of Transformation Initiatives Face a 'Momentum Gap' That Puts Value at Risk, NSP & Company Study Finds
-
CXAI Expands Agentic AI Reach into Mid-Market Through EngineRoom's Simpro Partnership
-
cbdMD Applauds Introduction of the Bipartisan Hemp Guardrails Act, Calling It a Win for Consumer Safety, American Jobs and Tax Revenue
-
Agency Guacamole's 10th B.L.N.D. Event Brought Industry Leaders Together for a Conversation on the Evolution of Diversity and Inclusion in Beauty
-
From Pilot to Production: InHand Networks' Practical Approach to Industrial Edge AI
The vaccines and treatments being developed for Ebola outbreak
There are no vaccines or treatments for the strain of Ebola that has killed nearly 200 people in DR Congo and Uganda, but several are being urgently developed in the hope of reining in the outbreak.
More than 800 cases of the Bundibugyo strain have been confirmed in the two countries, including 192 deaths, since the outbreak was declared on May 15.
However the true scale of the outbreak remains unknown, humanitarian organisations have warned, because the virus could still be spreading in remote, poor and conflict-wracked areas of the Democratic Republic of Congo.
To help address the crisis, scientists, pharmaceutical companies and funding bodies have been racing to develop new vaccines and treatments that can be swiftly and safely tested in humans.
Here are the main options being considered.
- Vaccines -
The vaccine candidate the World Health Organization has dubbed "most promising" is based on the rVSV platform used to make the only licensed Ebola vaccine.
The new jab has been tweaked to target Bundibugyo, rather than the more common Zaire strain.
The WHO has estimated it will take seven to nine months before the new vaccine is ready to be tested in humans.
Thomas Geisbert, a virologist at the University of Texas Medical Branch who developed both rVSV vaccines, told AFP that "this maybe could be accelerated to six-seven months".
Another vaccine candidate, which uses the ChAdOx1 platform that underpinned AstraZeneca's Covid-19 shot, could be ready sooner.
It is being developed by the University of Oxford along with the Serum Institute of India, the world's largest vaccine maker.
US pharma firm Moderna is working on its own Bundibugyo vaccine that uses the mRNA technology it pioneered against Covid.
The Oxford and Moderna vaccines could be ready to start phase 1 trials in humans in two to three months, the Coalition for Epidemic Preparedness Innovations (CEPI), a non-profit organisation that funds vaccine research, told AFP on Thursday.
"If things go smoothly, this could be as early as July," a CEPI spokeswoman added.
CEPI has pledged millions of dollars to help develop the three vaccine candidates.
The deputy CEO of CEPI, Aurelia Nguyen, told AFP the "three bets" were on vaccine platforms that all "have different advantages, but also different weaknesses".
It remains to be seen which could prove effective, but it was important to have "all chances on our side," she emphasised.
Nguyen also pointed out that it took two years to bring a 2018 outbreak of the Zaire strain in DR Congo and Uganda under control -- even though vaccine doses were ready to be shipped within 72 hours.
- Treatments -
The WHO has also recommended prioritising three treatments for swift trials.
One is called remdesivir, an antiviral made by US pharma firm Gilead that used to treat Covid. Some lab data has indicated it could also work for Bundibugyo, but it has not been tested against the strain in humans.
Antivirals like Remdesivir pretend to be an important piece of RNA, but do not connect the viral chain, therefore blocking the virus from being able to replicate.
Another drug recommended by WHO is a monoclonal antibody called MBP134, developed by Mapp Biopharmaceutical, which targets Ebola viruses including Bundibugyo.
Monoclonal antibodies are proteins made to work like the antibodies of the body's immune system.
The third is a different monoclonal antibody called Maftivimab, developed by Regeneron.
"These candidates are being evaluated and will be advanced into clinical studies in affected countries as quickly as possible," leading pharmaceutical lobby IFPMA said this week.
Another Gilead drug called obeldesivir, which is the oral form of the intravenous remdesivir, has also demonstrated an ability to protect monkeys against two other Ebola strains -- but not yet Bundibugyo.
M.O.Allen--AT